Validation of the mantle cell lymphoma international prognostic index: A single-center retrospective analysis

American Journal of Hematology

Volumn 85, Issue 6, 2010, Pages 454-456

  Smith, Stephen D ^a   Hsi, Eric ^a   Bolwell, Brian ^a   Pohlman, Brad ^a   Dean, Robert ^a   Effinger, Meagan ^a   Maggiotto, Amanda ^a   Sweetenham, John ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; RITUXIMAB; VINCRISTINE;

ADULT; AGED; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LETTER; LEUKEMIA RELAPSE; MALE; MANTLE CELL LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; VINCRISTINE;

EID: 77953070835     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21705     Document Type: Letter

References (29)

1. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 1994;84:1361-1392. (Pubitemid 24273002)
2. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009;27:511-518.
3. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013-7023.
4. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL network. Blood 2005;105:2677-2684.
5. Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the nordic lymphoma group. Blood 2008;112:2687-2693.
6. Damon LE, Johnson JL, Niedzwiecki D, et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009;27:6101-6108.
7. Hoster E, Metzner B, Forstpointner R, et al. Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2009;114:880.
8. Dreyling MH, Hoster E, Van Hoof A, et al. Early consolidation with myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission in mantle cell lymphoma: Long term follow up of a randomized trial of the. Blood (ASH Annual Meeting Abstracts) 2008;112:769.
9. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007;67:6745-6752. (Pubitemid 47105521)
10. LaCasce A, Vandergrift JL, Rodriguez MA, et al. R-CHOP, followed by high dose therapy and autologous stem cell rescue (HDT/ASCR), and R-Hyper-CVAD have equivalent progression-free survival and are superior to R-CHOP alone in younger patients with mantle cell lymphoma: A comparative effectiveness analysis from the national comprehensive cancer network (NCCN) non-Hodgkin's lymphoma outcomes database project. Blood (ASH Annual Meeting Abstracts) 2009;114:403.
11. A predictive model for aggressive non-Hodgkin's lymphoma. the international non-Hodgkin's lymphoma prognostic factors project. N Engl J Med 1993;329: 987-994.
12. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-1265.
13. Andersen NS, Jensen MK, de Nully Brown P, Geisler CH. A Danish population-based analysis of 105 mantle cell lymphoma patients: Incidences, clinical features, response, survival and prognostic factors. Eur J Cancer 2002;38:401-408.
14. Argatoff LH, Connors JM, Klasa RJ, et al. Mantle cell lymphoma: A clinicopathologic study of 80 cases. Blood 1997;89:2067-2078. (Pubitemid 27132123)
15. Moller MB, Pedersen NT, Christensen BE. Mantle cell lymphoma: Prognostic capacity of the follicular lymphoma international prognostic index. Br J Haematol 2006;133:43-49. (Pubitemid 43327196)
16. Samaha H, Dumontet C, Ketterer N, et al. Mantle cell lymphoma: A retrospective study of 121 cases. Leukemia 1998;12:1281-1287. (Pubitemid 28395993)
17. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558-565.
18. Hoster E, Hasford J, Hermine O, et al. Confirmation of the mantle cell lymphoma international prognostic index (MIPI) in an independent prospective patient cohort. Blood (ASH Annual Meeting Abstracts) 2009;114:Abstract 138.
19. Geisler CH, Kolstad A, Laurell A, et al. The mantle cell lymphoma prognostic index (MIPI) is superior to the international prognostic index (IPI) in predicting survival following intensive 1st-line immunochemotherapy and autologous stem-cell transplantation (ASCT). Blood 2010;115:1530-1533.
20. Terol M, Teruel A, Amat P, et al. Validation of the new prognostic index (MIPI) in mantle cell lymphoma: A single institution experience (abstract). Ann Oncol 2008;19:iv213.
21. Chiappella A, Puccini B, Rossi M, et al. Mantle cell international prognostic index (MIPI) is a strong predictor of the outcome of mantle cell lymphoma (MCL) in the rituximab (R) era (abstract). Blood (ASH Annual Meeting Abstracts) 2009;114:Abstract 2928.
22. Salek D, Vasova I, Pytlik R, et al. Mantle cell lymphoma international prognostic score is valid and confirmed in unselected cohort of patients treated in rituximab era (abstract). Blood (ASH Annual Meeting Abstracts) 2008;112: Abstract 3745.
23. Pan L, Guthrie KA, Till BG, et al. The mantle cell lymphoma international prognostic index (MIPI) at diagnosis is associated with survival of mantle cell lymphoma patients undergoing autologous hematopoietic stem cell transplantation. Blood (ASH Annual Meeting Abstracts) 2008;112:1143.
24. Eve HE, Gambell J, Smith P, et al. The simplified mantle cell lymphoma international prognostic index predicts overall survival but not progression-free survival in patients with mantle cell lymphoma treated with fludarabine and cyclophosphamide +/- rituximab: Results of a randomized phase II trial. Leuk Lymphoma 2009;50:1709-1711.
25. Tam CS, Bassett R, Ledesma C, et al. Mature results of the M. D. anderson cancer center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009;113:4144-4152.
26. Brepoels L, Stroobants S, De Wever W, et al. Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma 2008;49:1693-1701.
27. Gill S, Wolf M, Prince HM, et al. [18F]Fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymphoma Myeloma 2008;8:159-165.
28. Shah JJ, Fayad L, Romaguera J. Mantle cell international prognostic index (MIPI) not prognostic after R-hyper-CVAD. Blood 2008;112:2583; author reply 2583-2584.
29. Epner EM, Unger J, Miller T, et al. A multi center trial of HyperCVAD+Rituxan in patients with newly diagnosed mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2007;110:387.